Saturday, March 25, 2006


Hep C Virus - Hospital Practice: Chronic Hepatitis C: Early Intervention


Hospital Practice: Chronic Hepatitis C: Early Intervention
Chronic Hepatitis C: Early Intervention RAYMOND S. KOFF University of Massachusetts Chronic hepatitis C infection is the most common liver disease in the United States; it accounts for up to 12,000

Hepatitis C Factsheet - Liver Health Information - The American Liver
However, there is a low prevalence of the infection in long-term spouses of people with chronic hepatitis C virus who have no other risk factor for infection.

Interferon-alpha and Ribavirin in Treating Children and Young Adults
Interferon- and Ribavirin in Treating Children and Young Adults With Chronic Hepatitis C After Malignancy Herwig Lackner, MD * , Andrea Moser, MD * , Johann Deutsch, MD * , Harald H.

Friday, March 24, 2006


Hep C Virus - Intercell AG / Financial Figures/Balance Sheet / Intercell announces preliminary 2005 full year results: Good progress


Intercell AG / Financial Figures/Balance Sheet / Intercell announces preliminary 2005 full year results: Good progress
n-tv.de - Mar 05 10:31 PM
Disclosure announcement transmitted by euro adhoc.Save to My Web

AVI BioPharma Successful Ebola Study Results Highlighted in Nature Reviews Drug Discovery
[Press Release] Business Wire via Yahoo! Finance - Mar 07 6:00 AM
PORTLAND, Ore.----March 7, 2006--AVI BioPharma, Inc. , today announced that the February issue of Nature Reviews Drug Discovery chose to highlight the company's recent Ebola study results.Save to My Web

Coley Pharmaceutical Group Initiates Phase II Clinical Study of Actilon(TM) for Hepatitis C
[Press Release] PR Newswire via Yahoo! Finance - Feb 23 5:30 AM
Coley Pharmaceutical Group, Inc. today announced the initiation of a randomized Phase II clinical study of Actilon for the treatment of patients with chronic Hepatitis C infection.Save to My Web

Clinical Trial Results Show that Peregrine's First-In-Class Anti-Viral Agent Tarvacin(TM) is Safe and Well-Tolerated in
[Press Release] PR Newswire via Yahoo! Finance - Feb 27 4:00 AM
Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for viral diseases and cancer, today announced that it will present top line data demonstrating that its first-in-class anti-viral compound Tarvacin Anti-Viral appeared safe and well-tolerated in a Phase l study in chronic hepatitis C virus infected patients.Save to My Web

Schering-Plough and PTC Therapeutics Announce Collaboration for Development of PTC's Preclinical Hepatitis C Compounds
[Press Release] PR Newswire via Yahoo! Finance - Mar 20 5:30 AM
Schering-Plough Corporation and PTC Therapeutics, Inc. today announced that they have entered into an exclusive collaboration and licensing agreement for the development of PTC's preclinical compounds for the oral treatment of hepatitis C virus infection and other viral diseases.Save to My Web

Hep C Virus - VA National Hepatitis C Program


VA National Hepatitis C Program
The Veterans Affairs National Hepatitis C Web site provides information about viral hepatitis for health care providers inside and outside the VA system, ...

HCV Advocate: Hepatitis C Living with Hepatitis C
Welcome to HCVadvocate.org Here you will find information on hepatitis C (HCV), hepatitis C treatment options, articles, newsletters; information on ...

Hepatitis C: An Epidemic for Anyone
This public health awareness site, hosted by Dr. C. Everett Koop, provides extensive information about hepatitis C and the hepatitis c epidemic.

Thursday, March 23, 2006


Hep C Virus - National Hepatitis C Coalition Inc. - Offering Hope For Hepatitis C


National Hepatitis C Coalition Inc. - Offering Hope For Hepatitis C
The original nationwide hepatitis C coalition of patients and families, providing education and support through online communications, hep C hotline, ...

Hepatitis C
NEW: The Hepatitis C Sourcebook. By Howard J. Worman, MD. The Hepatitis C Virus (HCV). HCV was discovered in 1989 by investigators at Chiron, Inc. Portions ...

WHO | Fact sheets
Hepatitis C · Hepatitis E · HIV/AIDS: "3 by 5" progress · Human genetics and noncommunicable disease · Human rights, women and HIV/AIDS. Back to top ...

Hep C Virus - Hepatitis C (Advanced)


Hepatitis C (Advanced)
... for HCV RNA is a reliable way of demonstrating that hepatitis C infection is present and is the most specific test for ...

Hepatitis C (PDF)
... Hepatitis C. Hepatitis C infection is caused by a virus which ... intercourse without a condom. Sometimes hepatitis C infection may be ...

Hepatitis C Management
... RNA is a reliable way of demonstrating that hepatitis C infection is present and is the most specific ... 2a plus ribavirin for chronic hepatitis C infection. New England Journal of ...

Hep C Virus - A Summary of Chronic Hepatitis C InfectionHepatitis C

A Summary of Chronic Hepatitis C Infection

Hepatitis C is a stealthy virus that mutates while hiding in liver cells and other organ cells like the spleen and gall bladder. The fact that the viral cells "hide" makes it very difficult for the body's immune system to eradicate it. Hepatitis C is a slowly progressing disease sometimes taking many years until symptoms are noticeable. It is at this point that the virus has reached advanced chronic stage and becomes difficult to eradicate. Hepatitis C results in 8,000 to 10,000 deaths annually. Hepatitis C is also the leading cause of liver transplants in the U.S.

Hepatitis C infection is caused by blood contact with someone who has the virus infection himself. The transmission of the virus can occur by illicit drug use with needles, sharing toothbrushes or razors with an infected person, by sexual means, by unsanitary tattooing or by exposure to blood at your workplace (like a hospital or blood bank). Some HCV infection may have been caused by receiving blood from a transfusion prior to 1992.

Hepatitis C is diagnosed via a blood test. Usually, the first thing that is noticed is that the liver enzyme levels for ALT and AST are elevated well above normal levels. Further investigation via HCV-RNA testing identifies whether the Hepatitis C virus is in your blood or not. Other tests for HCV include qualitative viral load tests, which measure the RNA particles in your blood. If you are being treated for HCV, your doctor is probably using either a HCV-RNA or viral load test to determine the effectiveness of the treatment.

The symptoms of Hepatitis C infection often do not occur in a person until 20 years after he/she had been infected. Since the HCV infects the liver and the liver is the organ in the body that makes all the energy for our daily activities possible, liver function deterioration often results in fatigue. Fatigue is the primary complaint or symptom of HCV infection. Other more severe symptoms are jaundice (yellowing of the skin/eyes), bile retention (which can cause jaundice), portal vein hypertension, skin rashes and itching, and autoimmune problems resulting from your body's immune system attacking normal cells.

Long term HCV infection may result in fibrosis or even cirrhosis of the liver. Fibrosis results from unchecked liver inflammation. As the HCV infection progresses, the damage to the liver results in scarring or hardening of the liver cells (fibrosis). Long term fibrosis may lead to cirrhosis which is when the scarring from fibrosis overtakes the normal liver cell structure causing deformity and loss of function in the liver. About 15%-20% of HCV patients end up with cirrhosis. A liver biopsy is currently the most accurate means of determining the amount of inflammation and fibrosis the liver has sustained.

Hepatitis C progression in the body can take several years or even decades to come to chronic stage or to a stage where severe liver damage is evident. This period of time allows a person to determine how to properly treat the disease and to decide on a course of disease management. Currently, the main treatment for HCV infection to eradicate the virus is combo alpha-interferon and Ribavirin. Sometimes a doctor may prescribe interferon alone. Interferon comes in standard form or in pegylated form. Standard form interferon is administered 3 times per week, while the pegylated form is administered only once per week. Your body makes its own interferon, which is a protein that fights viral infection and viral replication.

Hepatitis C may often be managed by taking herbal and vitamin supplements that help your body fight infection and limit inflammation. These supplements help your liver with the inflammation and give it the nutrients it needs to regenerate healthy new cells. Your doctor can recommend alternative or adjunct solutions you may want to try.

Proper treatment of the disease, a healthy and active lifestyle, a good diet, abstinence from alcohol and stress management are important factors in controlling Hepatitis C progression.

About the Author

Greg Lietz is a freelance writer and internet businessman. His main website is http://www.theonlinebizplace.com where he provides content about internet based business opportunities and different niche interests. This article may be freely printed when the bio information is included.

Wednesday, March 22, 2006


Hep C Virus - Hepatitis C - silent epidemic


Hepatitis C - silent epidemic
Thunder Bay's Source, Canada - Feb 23, 2006... in attendance. The most common way to contract Hep C is through blood, and is often related to the sharing of needles. However thousands ...

Hep C symptom women need free care
Irish Medical Times, Ireland - Mar 8, 2006Dr Jerry Cowley, Mayo Independent TD, has called on the Government to provide free health care for a number of women suffering from Hepatitis C symptoms. ...

Daily Planner: Monday
Enterprise-Record, CA - Mar 20, 2006... 538-7341. Call for an appointment. Weekly. HEP C/STD TESTING: 8 am to 5 pm Fee or free depending on eligibility. Butte County Public ...

Human Genome Sciences Seen Partnering Hep C Drug In 2006
Forbes - Mar 16, 2006Piper Jaffray maintained an "outperform" rating on Human Genome Sciences and advised investors to buy on recent weakness in the stock. ...

Hep C Virus - XTL Biopharmaceuticals Announces Financial Results for the Year ...


XTL Biopharmaceuticals Announces Financial Results for the Year ...
PR Newswire (press release), NY - Mar 20, 2006... XTL-2125 is expected to enter Phase 1 clinical trial in chronic hepatitis C patients in 1H 2006. XTL is also developing XTL-6865 ...

Novelos Therapeutics Closes $15 Million Private Placement
International News Service, Australia - Mar 7, 2006... NOV-002 in lung cancer, in addition to our other clinical development programs, including chemotherapy-resistant ovarian cancer and chronic hepatitis C with NOV ...

Hepatitis C Treatment for People With Severe Mental Illness
Psychosomatics (subscription) - Feb 28, 2006... Chander G, Sulkowski MS, Jenckes MW, et al: Treatment of chronic hepatitis C: a systematic review. Hepatology 2002; 36(suppl1):S135-144. ...

Coley Pharmaceutical Group Reports Fourth Quarter and Full Year ...
MSN Money - Feb 23, 2006... is being evaluated alone and in combinations with drugs which comprise the current standard of care for the treatment of chronic Hepatitis C infection in ...

Monday, March 20, 2006


Hep C Virus - InterMune to Present at the 5th Annual JMP Securities Research Conference


InterMune to Present at the 5th Annual JMP Securities Research Conference
[Press Release] PR Newswire via Yahoo! Finance - Mar 02 1:01 PM
InterMune, Inc. announced today that Dan Welch, President and CEO of InterMune, will present a corporate overview at the 5th Annual JMP Securities Research Conference in San Francisco on Thursday, March 9, 2006 at 1:15 p.m.Save to My Web

MIGENIX Reports Third Quarter Fiscal Year 2006 Results
T-Net British Columbia - Mar 08 9:39 AM
Jim DeMesa, M.D., President & CEO of MIGENIX stated, "We continue to make excellent progress in our development programs, with two phase II clinical outcomes expected this year in our MX-3253 program for the treatment of chronic hepatitis C virus infections and a phase III clinical outcome for CPI-226 in catheter-related infections in the first half of calendar 2007. These outcomes have the Save to My Web

Human Genome Sciences Seen Partnering Hep C Drug In 2006
Forbes - Mar 16 10:32 AM
Piper Jaffray reiterated an "outperform" rating and $20 price target on the biotech firm.Save to My Web

Intercell AG / Financial Figures/Balance Sheet / Intercell announces preliminary 2005 full year results: Good progress
n-tv.de - Mar 05 10:31 PM
Disclosure announcement transmitted by euro adhoc.Save to My Web

Hep C Virus - Aidsmap | HCV treatment failure not due to change in HCV genotype in HIV-positive IDUs


Aidsmap | HCV treatment failure not due to change in HCV genotype in HIV-positive IDUs
YOU ARE HERE: HCV treatment failure not due to change in HCV genotype in HIV-positive IDUs. Chris Gadd, Monday, September 12, 2005 ... co-infected with hepatitis C virus (HCV) and HIV do not appear to fail HCV therapy due to a shift in ...

Hepatitis C Resources and Information
Hepatitis C Resources and Information is a website with up-to-date hepatitis C weblinks, hep C information, HCV defined and undefined, inspiration for people who have hepatitis C and their families and so much more. ... I'm here to help you find Hepatitis C (HCV) information and I plan on helping you enjoy smooth ... helpful stuff about Hepatitis C (HCV) and he had the site looking ...

Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease
... Alanine aminotransferase. Anti-HCV Antibody to HCV that develops in response to HCV infection ... Hepatocellular carcinoma. HCV Hepatitis C virus. HCV-positive Positive for anti-HCV ...

Sunday, March 19, 2006


Hep C Virus - Hep C key lies in new needles, not education


Hep C key lies in new needles, not education
Australian, Australia - Feb 19, 2006PROVIDING clean needles to injecting drug users is almost four times more effective in fighting the rising epidemic of hepatitis C than the education and ...

Putting a face on the AIDS tragedy
Toronto Star, Canada - Feb 23, 2006... was around the middle of 1985 that the reality of AIDS was descending upon Canada's hemophiliac community, says John Plater, chair of the HIV/Hep C Task Force ...

Daily Planner: Monday
Enterprise-Record, CA - Mar 13, 2006... 538-7341. Call for an appointment. Weekly. HEP C/STD TESTING: 8 am to 5 pm Fee or free depending on eligibility. Butte County Public ...

'Silent killer' driven out of the shadows: Hepatitis
Chillicothe Gazette, OH - Feb 20, 2006... "That's why the message needs to get out that, guess what - get tested for hep C because the cure rate goes up every year," he says. ...

Hep C Virus - Newer Hepatitis B Drug Bests Standard Treatment


Newer Hepatitis B Drug Bests Standard Treatment
Title: Newer Hepatitis B Drug Bests Standard TreatmentCategory: Health NewsCreated: 3/9/2006 1:58:00 AMLast Editorial Review: 3/9/2006 1:58:03 AM

Pharma Stocks Flex Some Muscle
Blink: Hepatitis C Added by mfeed Forbes - Drug stocks exhibited yet another week of strength despite constant chatter regarding shrinking growth opportunities and safety risks. Meanwhile, biotechnology shares ended two weeks of declines but pulled back as they approached new highs for the ...... Read more... Discover Cool Software

Share and Discover Hepatitis C from Anywhere.
Add Hepatitis C to your Google Toolbar to Share and Discover Hepatitis C from Anywhere.

Doctor: Getting the Most from Your Doctor s Appointment
Title: Doctor: Getting the Most from Your Doctor s AppointmentCategory: Doctor's ViewsCreated: 5/13/2005Last Editorial Review: 5/13/2005

Hep C Virus - Hepatitis C (infectious liver inflammation type C)


Hepatitis C (infectious liver inflammation type C)
Hepatitis is the Latin word for liver inflammation. Type C hepatitis is caused by a virus called hepatitis C virus. It was previously referred to as ...

Introduction: Chronic Hepatitis C - WrongDiagnosis.com
Information on Chronic Hepatitis C as a medical condition with Chronic Hepatitis C information including symptoms, diagnosis, misdiagnosis, treatment, ...

Hepatitis Information Network - HepNet
Dr. Howard Worman summarizes a recent paper ''Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C'' published in Gastroenterology ...

Viral Hepatitis: A Through E and Beyond
Chronic hepatitis C: drug treatment with peginterferon alone or combination treatment with peginterferon and the drug ribavirin. ...